Production (Stage)
Perspective Therapeutics, Inc.
CATX
$2.39
-$0.12-4.78%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.60% | 1.39% | 351.13% | 78.32% | -44.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.60% | 1.39% | 351.13% | 78.32% | -44.27% |
| Cost of Revenue | 92.01% | 129.16% | 2,212.97% | -- | 1,643.64% |
| Gross Profit | -96.72% | -137.61% | -3,903.07% | -3,275.15% | -2,343.83% |
| SG&A Expenses | 40.92% | 26.34% | 36.63% | 26.11% | 47.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 200.00% | 200.00% | -- |
| Total Operating Expenses | 68.58% | 61.06% | 98.97% | 95.79% | 129.83% |
| Operating Income | -71.07% | -63.15% | -89.78% | -96.36% | -157.60% |
| Income Before Tax | -104.07% | -100.54% | -69.29% | -85.02% | -157.06% |
| Income Tax Expenses | -126.72% | 20.90% | 174.75% | 174.75% | 174.75% |
| Earnings from Continuing Operations | -68.11% | -109.14% | -204.48% | -287.81% | -733.61% |
| Earnings from Discontinued Operations | 93.93% | 89.54% | -56.87% | -122.13% | -448.84% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.79% | -70.46% | -154.12% | -213.73% | -497.11% |
| EBIT | -71.07% | -63.15% | -89.78% | -96.36% | -157.60% |
| EBITDA | -116.25% | -111.92% | -88.77% | -95.39% | -157.53% |
| EPS Basic | 36.16% | 27.43% | -49.85% | -79.88% | -178.83% |
| Normalized Basic EPS | 33.27% | 41.69% | 8.95% | -7.37% | -49.67% |
| EPS Diluted | 5.99% | -6.96% | -49.85% | -79.88% | -178.83% |
| Normalized Diluted EPS | 33.27% | 41.69% | 8.95% | -7.37% | -49.67% |
| Average Basic Shares Outstanding | 109.84% | 140.75% | 130.75% | 117.35% | 104.12% |
| Average Diluted Shares Outstanding | 109.84% | 140.75% | 130.75% | 117.35% | 104.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |